Rua Bioscience Limited (NZE:RUA)
New Zealand
· Delayed Price · Currency is NZD 0.0280
0.00 (0.00%)
At close: Dec 5, 2025
Rua Bioscience Income Statement
Financials in millions NZD. Fiscal year is July - June.
Millions NZD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2019 - 2020 |
| Operating Revenue | 1.51 | 0.09 | 0.36 | 0.02 | - | Upgrade
|
| Other Revenue | 0.32 | 0.23 | 0.31 | 0.62 | 0.36 | Upgrade
|
| Revenue | 1.83 | 0.32 | 0.67 | 0.65 | 0.36 | Upgrade
|
| Revenue Growth (YoY) | 477.39% | -52.68% | 3.63% | 79.53% | - | Upgrade
|
| Cost of Revenue | 0.98 | 0.2 | 0.34 | 0.13 | - | Upgrade
|
| Gross Profit | 0.85 | 0.11 | 0.33 | 0.52 | 0.36 | Upgrade
|
| Research & Development | 0.94 | 1.18 | 1.59 | 2.98 | 1.9 | Upgrade
|
| Other Operating Expenses | 3.24 | 3.55 | 5.18 | 5.12 | 4.74 | Upgrade
|
| Operating Expenses | 4.18 | 4.73 | 6.77 | 8.1 | 6.64 | Upgrade
|
| Operating Income | -3.33 | -4.62 | -6.44 | -7.58 | -6.28 | Upgrade
|
| Interest Expense | -0.16 | -0.02 | -0.02 | -0.04 | -0.03 | Upgrade
|
| Interest & Investment Income | 0 | 0.13 | 0.2 | 0.14 | 0.05 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -3.49 | -4.51 | -6.25 | -7.49 | -6.27 | Upgrade
|
| Impairment of Goodwill | - | -8.25 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.03 | -0.53 | - | 0 | - | Upgrade
|
| Asset Writedown | - | -0.43 | -5.57 | - | - | Upgrade
|
| Other Unusual Items | 0 | - | 5.86 | - | 0.09 | Upgrade
|
| Pretax Income | -3.46 | -13.72 | -5.96 | -7.49 | -6.17 | Upgrade
|
| Income Tax Expense | - | - | 0 | 1.15 | -1.76 | Upgrade
|
| Net Income | -3.46 | -13.72 | -5.96 | -8.64 | -4.42 | Upgrade
|
| Net Income to Common | -3.46 | -13.72 | -5.96 | -8.64 | -4.42 | Upgrade
|
| Shares Outstanding (Basic) | 195 | 158 | 154 | 144 | 127 | Upgrade
|
| Shares Outstanding (Diluted) | 195 | 158 | 154 | 144 | 127 | Upgrade
|
| Shares Change (YoY) | 23.01% | 2.95% | 6.63% | 13.17% | 30.68% | Upgrade
|
| EPS (Basic) | -0.02 | -0.09 | -0.04 | -0.06 | -0.03 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.09 | -0.04 | -0.06 | -0.03 | Upgrade
|
| Free Cash Flow | -2.79 | -3.74 | -5.99 | -7.25 | -5.85 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.02 | -0.04 | -0.05 | -0.05 | Upgrade
|
| Gross Margin | 46.54% | 35.47% | 49.21% | 80.06% | 100.00% | Upgrade
|
| Operating Margin | -182.57% | -1459.98% | -962.92% | -1175.69% | -1748.19% | Upgrade
|
| Profit Margin | -189.19% | -4336.57% | -891.46% | -1338.73% | -1229.48% | Upgrade
|
| Free Cash Flow Margin | -152.79% | -1181.50% | -896.65% | -1123.09% | -1627.85% | Upgrade
|
| EBITDA | -3 | -4.28 | -5.85 | -6.94 | -5.69 | Upgrade
|
| EBITDA Margin | -164.01% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.34 | 0.34 | 0.58 | 0.64 | 0.6 | Upgrade
|
| EBIT | -3.33 | -4.62 | -6.44 | -7.58 | -6.28 | Upgrade
|
| EBIT Margin | -182.57% | - | - | - | - | Upgrade
|
| Revenue as Reported | 1.9 | 0.32 | 6.53 | 0.65 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.